Phase 2 N=21 Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
Prostate Cancer
Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=61 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Prostate Adenocarcinoma · PSA Failure · Recurrent Prostate Carcinoma
Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants
Phase 2 N=6 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
GBM · Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…
N/A N=10 A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine
Prostate Cancer
Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants
N/A N=504 Protecta Smart Analysis Register
Patients With an Indication for an ICD Implantation According to the Guidelines
Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock
Phase 3 N=356 Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Prostate Cancer
Primary: Specificity — 92.9; 93.8; 96.9 percentage
Phase 3 N=346 Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Prostate Cancer
Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up
N/A N=19 Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
Prostate Cancer
Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants
Phase 3 N=385 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer
Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true
N/A N=480 Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
Phase 2 N=20 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
Prostate Cancer · Prostate Cancer Metastatic
Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05
Phase 2 N=1,435 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer · Prostate Adenocarcinoma · Prostate Cancer Metastatic
Primary: Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer on a Per-patient Basis Confirmed by Histopathology. — 87.3 percentage of times value is…
Phase 3 N=22 68Ga PSMA in Preprostatectomy Patients
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection of Regional Pelvic Nodal Metastases on a Per Patient…
Phase 3 N=163 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Patients Reporting Adverse Reactions — 0 Participants
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Phase 2 N=50 Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
Recurrent Prostate Cancer
Primary: Number of Participants Who Develop a Strong or Modest Anti-PSA Immune Response — 12; 14; 6; 3 participants
N/A N=31 Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
Adenocarcinoma of the Prostate
Primary: Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT — 21; 5; 5 Participants
Phase 2 N=294 ARTS - AVODART After Radical Therapy For Prostate Cancer Study
Neoplasms, Prostate · Prostate Cancer After a Radical Treatment
Primary: Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days) — 365.5; 458.0; NA; NA days — p=<0.001
Phase 2 N=26 Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
Metastasis From Malignant Tumor of Prostate (Disorder)
Primary: Region-Level Correct Localization Rate (CLR) — 86.67; 86.67; 76.67; 80.00 percentage of Regions
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
N/A N=812 Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening
Prostate Cancer
Primary: Percentage of Patients Who Were Ready to Make a Decision or Were Undecided — 134; 90; 144; 125 Participants
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
N/A N=161 Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men
Prostate Cancer
Primary: Shared Decision-making — 12.54; 12.15 Units on a scale — p=0.8388
Phase 3 N=391 Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Prostate Cancer
Primary: Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT — 54.1; 51.4; 51.6; 46.2 percentage
Phase 2 N=80 68 Ga-PSMA for High Risk Prostate Cancer
Prostate Cancer · High Risk
Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants
N/A N=507 Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result
Prostatic Neoplasms
Primary: Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) — 466; 102; 364; 235 participants
Phase 3 N=299 Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
Prostate Cancer
Primary: Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy — .43 proportion of participants
N/A N=25 Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
Prostate Cancer
Primary: Prostate Cancer Detection Within the Prostate Gland by Copper Cu 64 TP3805 PET — 25 Participants